e-ISSN: 2319-9865
p-ISSN: 2322-0104

Journal of Medical and Health Sciences

Common Denominator in Liver Disease: A communication report; Focus on Reversing the Scarring that's Common to Liver Diseases

Indranil C*

*Bharat Technology, Maulana Abul Kalam Azad University of Technology, West Bengal, India

Commentary

Received: 17/09/2016
Accepted: 23/09/2016
Published: 30/10/2016

***For Correspondence**

Indranil C, Bharat Technology, Maulana Abul Kalam Azad University of Technology, west Bengal, India.

E-Mail: indranil.chax@gmail.com

Keywords: Pharmacology, disease, fibrosis, skin, liver patients

ABSTRACT

Collette Thain took a cruise to Ireland from her home in Edinburgh, Scotland to watch a rugby clash in 1994; she became ill al of a sudden and was accepted with abstruse signs of alarmist failure. Months later, Collette was diagnosed with a attenuate alarmist ache alleged primary biliary cirrhosis (PBC1). Her doctor said there were no accustomed treatments available, and she had about 5 years to live. About 40% of PBC patients do not respond. For them, the ache progresses and adversity continues. Ultimately, the alone advantage is alarmist transplantation, which isn't consistently accessible due to the curtailment of agency donors. In addition, it's an austere action with abiding implications. Researchers are alive on another for these patients. Testing of a new admixture has amorphous in patients with PBC who do not acknowledge to the accepted therapy. The admixture ability accept an added reach, however, because lab studies advance that it combats alarmist scarring, which occurs in all accepted forms of alarmist disease. Researchers in Discovery Pharmacology at the Genomics Institute of the Novartis Research Foundation has apparent a new admixture that could advice in PBC patients to do acknowledge.

REPORT OVERVIEW

When Collette Thain took a trip to Ireland from her home in Edinburgh, Scotland to watch a rugby tournament in 1994, she never expected to end up in the hospital. She became ill suddenly and was admitted with mysterious signs of liver failure.

Months later, Collette was diagnosed with a rare liver disease called primary biliary cirrhosis (PBC1). Her doctor said there were no approved treatments available, and she had about five years to live. Collette, then 37 and a mother of young children, was flabbergasted. "I asked the doctor, 'Do you at least have a leaflet?'" she says. "But he wasn't aware of any resources for me."

A few years later, Collette began taking ursodeoxycholic acid after it was approved for the treatment of PBC. She responded well and is still taking it today. But about 40% of PBC patients do not respond. For them, the disease progresses and suffering continues. Ultimately, the only option is liver transplantation, which isn't always possible due to the shortage of organ donors. In addition, it's a serious procedure with long-term implications.

Researchers are working on an alternative for these patients. Testing of a new compound has begun in patients with PBC who do not respond to the standard therapy. The compound might have a wider reach, however, because lab studies suggest that it combats liver scarring, which occurs in all common forms of liver disease.

"Unless the disease is caused by a hepatitis B or C virus, we are generally relying on archaic treatments for it," says Nikolai Naoumov, a seasoned hepatologist and Therapeutic Area Head of the liver program at Novartis Pharmaceuticals [1-19].

Take non-alcoholic steatohepatitis (NASH), or fatty liver disease, which is increasingly common due to the worldwide obesity epidemic. As fat builds up in the liver, the organ becomes inflamed and damaged. There are no approved therapies for NASH. It is on the rise in Asia, the Middle East and Latin America and has become the primary cause of chronic liver disease in North America and Europe. In the United States, it is now the second leading cause of liver transplantation [20-50].

e-ISSN: 2319-9865
p-ISSN: 2322-0104

“There is a tidal wave of metabolic liver disease sneaking up on us,” says Michael Badman, Translational Medicine Expert at the Novartis Institutes for Biomedical Research. “We want to provide patients with treatment options beyond liver transplants.”

SCARRING: THE COMMON PATH OF LIVER DISEASE PROGRESSION

Most forms of alarmist ache chase the aforementioned trajectory. It starts with a trigger, such as a virus or booze abuse. In PBC, the activate is an autoimmune acknowledgment that afield destroys acerbity ducts in the liver, and in NASH, it is a accession of fat in the liver. The activate initiates a abandoned aeon of abiding deepening and alarmist scarring alleged fibrosis. If untreated, fibrosis becomes cirrhosis, which can advance to alarmist abortion and, barring a transplant, death.

“Whatever the insult to the alarmist is, the accepted pathobiology of alarmist accident follows the aforementioned pathway,” says Naoumov.

For a continued time, the abstraction that an aching alarmist could alleviate (link is external) was advised a non-starter a part of alarmist specialists, but in contempt years, there is accretion affirmation suggesting that accretion is accessible even in late-stage disease. In abstracts in mice, the new admixture had an anti-scarring effect, suggesting that it ability be accessible to acceleration alarmist healing with medicine.

Scarring in the alarmist resembles the scarring of the skin. Injuries are repaired with coarse tissue rather than anatomic cells. This blister tissue blocks the breeze of claret and added biochemical through the liver, initiating an alternation acknowledgment that causes damage.

For instance, the alarmist produces acerbity acerbic to aid digestion. Acerbity acerbic dissolves fats in the digestive amplitude abundant the way laundry soap washes abroad stains. But in a aching liver, acerbity acerbic gets ashore and causes added scarring. “Instead of abandoning fats, acerbity acerbic trapped in the alarmist will deliquesce things like corpuscle membranes and could cause beef to die,” says Bryan Laffitte, Director of Discovery Pharmacology at the Genomics Institute of the Novartis Research Foundation.

The new compound, which was apparent by Laffitte’s group, is advised to breach this cycle. It harnesses the body’s congenital mechanisms for arresting with balance acerbity acid, which builds up in the alarmist in both PBC and NASH. These mechanisms are absolute by a receptor in alarmist and civil beef alleged FXR that detects acerbity acerbic and launches careful measures. The physique turns these processes on naturally, but we’re aggravating to about-face them on more.

One way to actor the accustomed activate that flips on the FXR adept about-face is to actualize an admixture that is acquired from a acerbity acid. But acerbity acids can as well could cause exceptionable ancillary effects, such as astringent itching. The Novartis admixture is not acquired from an acerbity acerbic and is advised to abbreviate the abeyant for itch.

Itch is of accurate affair for PBC patients. As a evidence of PBC, some acquaintance a maddening crawling all over the body, “like an army of all-overs beneath the skin,” says Collette, who directs the PBC Foundation accommodating advancement accumulation and adventures PBC-related crawling on occasion [51-80].

CLINICAL TESTING BEGINS

Researchers plans to test its new experimental compound in diseases in which bile acid accumulation causes fibrosis and disease progression, such as PBC and NASH. For instance, a clinical trial has begun and will recruit up to 95 PBC patients who have not responded to standard therapy.

This trial follows the strategy of focusing first on a small and specific group of patients who are likely to benefit and are also in need of therapeutic options, says Dr. Badman, who is designing the trials to test the new compound. The knowledge gained from this initial trial can be put to use in future trials of more complex diseases, like NASH, which progresses in less predictable ways [81-100].

CONCLUSION

Collette still suffers from intense fatigue from PBC, and she still lives day-to-day, despite ongoing treatment. “For so many years there has been little progress for PBC,” she says. “This new compound gives us hope.” Itch is of authentic activity for PBC patients. As an affirmation of PBC, some associate a maddening ample all over the body, “like an army of all-overs below the skin,” says Collette, who directs the PBC Foundation all-around advance accession and adventures PBC-related ample on occasion. The action of absorption aboriginal on a baby and specific accumulation of patients who are acceptable to account and are as well in charge of ameliorative options, this antecedent balloon can be put to use in approaching trials of added circuitous diseases, like NASH, which progresses in beneath anticipated ways.

e-ISSN: 2319-9865
p-ISSN: 2322-0104

REFERENCES

1. Loomba, R. and Sanyal, A.J. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013; 10:686–690.
2. Wong, R.J., Aguilar, M., Cheung, R. et al, Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555.
3. Cooper CL and Cameron DW. Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV. Clin Infect Dis. 2005;41:S105-S109.
4. Lin W, et al. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology. 2008;134:803-811.
5. Rizza SA, et al. TRAIL dependent fratricidal killing of gp120 primed hepatocytes by hcv core expressing hepatocytes. PLoS One. 2011;6:e27171.
6. Danta M, et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis. 2008;197:1558-1566.
7. Kim AY, et al. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med. 2006;3:e492.
8. Benhamou Y, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054-1058.
9. Monga HK, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis. 2011;33:240-247.
10. Martinez-Sierra C, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients co-infected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis. 2003;36:491-498.
11. Goutagny N, et al. Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection. J Infect Dis. 2003;187:1951-1958.
12. Blackard JT, et al. Extrahepatic replication of HCV: Insights into clinical manifestations and biological consequences. Hepatology. 2006;44:15-22.
13. Lanford RE, et al. Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR. J Virol. 1995;69:8079-8083.
14. Blackard JT, et al. Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV-coinfected persons. J Infect Dis. 2005;192:258-265.
15. Laskus T, et al. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis. 2000;181:442-448.
16. Minosse C, et al. Possible compartmentalization of hepatitis C viral replication in the genital tract of HIV-1-coinfected women. J Infect Dis. 2066;194:1529-1536.
17. Corrado Pedrazzani, et al. update on laparoscopic treatment of gastrointestinal stromal tumors. J Integr Oncol. 2016;S1:004.
18. Sang Ngoc Nguyen. Case report: wilm's tumor. adv oncol res treat. 2016;1:1.
19. Bo Na Lee, et al. Leiomyosarcoma of the ovary mimicking gastrointestinal stromal tumor originating from small bowel: a case report and literature review. Gynecol Obstet. 2016;6:359.
20. Guozheng Liu. A clearance step will become increasingly crucial for pretargeted tumor therapy when tumor accumulation is improved. J Cancer Clin Trials. 2006;3:54-55.

21. Vlad Teodor Berbecar, et al. Large borderline ovarian tumor: a case report. surgery curr res. 2016;3:5.
22. Taha MS and Alnemari HH. Skull base reconstruction with titanium mesh for benign complex anterior skull base tumors: case series and review of the literature. J Brain Tumors Neurooncol. 2016;1:104.
23. Paul J Akhenblit and Mark D Pagel. Recent advances in targeting tumor energy metabolism with tumor acidosis as a biomarker of drug efficacy. J Cancer Sci Ther. 2016;8.1:20-29.
24. Manjul Tiwari. adenomatoid odontogenic tumor: an extra follicular variant in the mandible of 12 years old pediatric female patient. Oral Health Case Reports. 2016;3:56-58.
25. Heissner K, et al. Treatment associated interstitial pulmonary toxicity of temozolomide plus bevacizumab for locally advanced solitary fibrous tumor. J Pulm Respir Med. 2016;6:314.
26. Shunsuke Sakuraba, et al. A case of pfetin negative gastrointestinal stromal tumor (gist), metastasized to the liver five years after surgery: a surgical challenge. J Mol Biomark Diagn. 2016;S8:014.
27. Salomao-Junior A, et al. Evaluation of tumor growth in treatment of murine melanoma by transdermal infusion of etoposide by radiofrequency. J Clin Exp Dermatol Res 2016; 7:325.
28. Emre Demirci, et al. Intraindividual Tumor heterogeneity in neuroendocrine tumors revealed with 18F-FDG and 68Ga-DOTA-TATE PET/CT. J Nucl Med Radiat Ther. 2016;7: 277.
29. Shaoli Song, et al. Giant solitary fibrous tumor of posterior mediastinum: a case report. J Nucl Med Radiat Ther. 2016;7:276.
30. Zhijun Wang and Qing Wang. Numerical simulation of a tumor growth dynamics model using particle swarm optimization. J Comput Sci Syst Biol. 2015;9:01-05.
31. Daohong Chen and Xiaoshi Zhang. Tipping tumor microenvironment against drug resistance. Oncol Trans Res. 2015;3:56-58.
32. Tamara Aleksic, et al. Improved immunohistochemical detection of type 1 insulin-like growth factor receptor in human tumors. immunochem immunopathol. 2016;2:114.
33. Florence Lai Tiong. About the rare case of a pelvic primitive neuro-ectodermal tumor in a 37 year old patient. J Clin Case Rep. 2015;5:664.
34. Malik S, et al. Recurrent malignant phylloides tumor: a rare entity. J Cytol Histol. 2006;3:5-8.
35. Vishnuvarthanan Govindaraj, et al. Short notes on unsupervised learning method with clustering approach for tumor identification and tissue segmentation in magnetic resonance brain images. J Clin Exp Neuroimmunol. 2016; 1:101.
36. Linda Ziani, et al. Cancer-associated fibroblasts and modulation of the antitumor immune response. J Mol Genet Med. 2015;9:193.
37. Michael Lam, et al. Systemic inflammation impact on tumor biology and outcomes in colorectal cancer. J Clin Cell Immunol. 2015;6:377.
38. Jyotshna Kanungo. Tumor suppressors and endodermal differentiation of p19 embryonic stem cells. Cell Dev Biol. 2015;4:E138.
39. Alexander Lu and Lijuan Zhang. Tumor-dependent and -independent serum/plasma biomarkers for early diagnosis of lung cancer. Transl Med (sunnyvale). 2016;6:160.
40. Xiaoyi Wang and Weiyue Lu. Active targeting liposomes: promising approach for tumor-targeted therapy. J Bioequiv Availab. 2016;5:161.
41. Rios WM, et al. fusion of glioblastoma tumor antigens to herpes simplex virus-1 glycoprotein d enhances secondary adaptive immune responses in a dna vaccine strategy. J Vaccines Vaccin. 2016;5:11.
42. Alzoobaee Saif, et al. A 16 year old girl with atypical bronchial carcinoid tumor. Neonat Pediatr Med. 2016;5:101.

43. Timothée Jacquesson and Emmanuel Jouanneau. An unusual giant brain tumor: from where is it starting?. Anat Physiol. 2016;1:192.
44. Emily Hinchcliff. Surgical management of an extragonadal trabecular carcinoid tumor: a case report and review of the literature. Arch Surg Oncol. 2015;1:1.
45. Qader MM , et al. Production of antitumor antibiotic gkk1032b by penicillium citrinum, an endophytic fungus isolated from garcinia mangostana fruits. Med Aromat Plants. 2016;5:225.
46. Kim H, et al. Identification of tumor subtypes of endometrial carcinoma by integration of heterogeneous datasets. J Med Diagn Meth. 2016;5:225.
47. Lei Zouet al. Size Effects of nanocomplex on tumor associated macrophages targeted delivery for glioma. J Nanomed Nanotechnol. 2015;6:339.
48. HançerlioÃ„et al. Our three year clinical experience at appendiceal incidental neoplasms and management of appendicial tumors. J Clin Exp Pathol 2015;5:260.
49. Chakraborty PP, et al. A Look Inside the Pancreas: The “Endocrine-Exocrine Cross-talk”. Endocrinol Metab Synd. 2015;4:160.
50. Pezzilli R. Pancreatic Exocrine Insufficiency Following Pancreatic Resection. Pancreatic Dis Ther. 2011; 1:e102.
51. Zippi M, et al. Intraductal Papillary Mucinous Neoplasm Associated to Pancreas Divisum. J Gastroint Dig Syst. 2014;4:171.
52. Dima AC, et al. Intraductal Papillary Mucinous Neoplasm of the Pancreas; Up-to-Date. Journal of Surgery [Jurnalul de chirurgie]. 2015;11:99-101.
53. Goh BKP. Current Guidelines for the Management of Branch Duct Intraductal Papillary Mucinous Neoplasms. Pancreat Disord Ther. 2014;4:e134.
54. Kimura W, et al. Acute Pancreatitis is a Predictive Factor for Malignancy in Mixed or Main Duct Intraductal Papillary Mucinous Neoplasms. Pancreat Disord Ther. 2015;5:148.
55. Mathias R and Weid VD PY. Immunity and gastrointestinal disease:arole for lymphatic vessels. J Clin Cell Immunol 2014;5:262.
56. Chua CS, et al. PTEN hamartoma tumour syndrome:gastrointestinal manifestations of two cases diagnosed in singapore. Hereditary Genet 2105;4:148.
57. Gonzalez RG, et al. A rare case of gastrointestinal obstruction:bouveret syndrome. J Gastrointest Dig Syst 2015;5:277.
58. Serrato JAT, et al. Gastrojejunal stenosis of gastric bypass in laparoscopic bariatric surgery:report of a case. J gastrointest Dig Syst 2015;5:275.
59. Eisapour M, et al. Comparative radular morphology in some intertidal gastropods along hormozgan province, iran. J Aquac Res Development 2015;6:322.
60. 79. Gimenez-Sanchez F, et al. A matched case-control study measuring the effectiveness of the rotavirus vaccines to prevent gastroenteritis hospitalizations . J Vaccines Vaccin 2015;6:275.
61. Muelbert M, et al. Fruit and vegetable consumption in patients with gastrointestinal cancer. J Nutr Food Sci 2015;5:356.
62. Gaba M and Mohan C. Design, synthesis and biological evaluation of novel 1, 2, 5-substituted benzimidazole derivatives as gastroprotective antiinflammatory and analgesic agents. Med chem 2015;5:058-063.
63. Gerlach H, et al. Oral application of charcoal and humic acids influence selected gastrointestinal microbiota, enzymes, electrolytes, and substrates in the blood of dairy cows challenged with glyphosate in gmo feeds. J Environ Anal Toxicol 2014;5:256.
64. Huynh D and Nguyen NQ. Gastrointestinal dysfunction in chronic liver disease. J Gastrointest Dig Syst 2015;5:257.
65. Jumpertz S, et al. Role of the cop9 signalosome in gastrointestinal cancers. J Carcinog Mutagen 2105;6:210.

66. Moldovan B, et al. Left side first approach in nissen procedure for gastroesophageal reflux disease;how we do it. Journal of Surgery [Jurnalul de chirurgie] 2014;10:255-259.
67. Iwai K, et al. Utility of upper gastrointestinal endoscopy for management of patients with roundup® poisoning. J Clin Toxicol 2014;4:218.
68. Moe TO, et al. Thyrotoxicosis in an elderly patient simulating infectious gastroenteritis. J Clin Case Rep 2014;4:454.
69. Mengoli MC, et al. Epidemiologic, clinicopathological, immunohistochemical and molecular analysis of gastrointestinal glomus tumors. J Clin Exp Pathol 2014;4:189.
70. Serefettin M. Gastrointestinal stromal tumors, interstitial cells of cajal and their nomenclature. J Gastroint Dig Syst 2014;4:231.
71. Al-Jashamy KA. Colorectal Cancer. OMICS Group eBooks, Foster City, USA, In press.
72. Ahmad A, et al. Endocrine Tumors. OMICS Group eBooks, Foster City, USA, 2015.
73. https://www.pancan.org/section-facing-pancreatic-cancer/learn-about-pan-cancer/types-of-pancreatic-cancer/
74. Moyana TN, et al. An Analysis of Prognostic Factors in Pancreatic Neuroendocrine Tumors. J Clin Exp Pathol. 2016;6:284.
75. https://www.omicsonline.org/endocrinology-metabolic-syndrome/endocrine-oncology.php
76. Pop Radu C. [Pulmonary Neuroendocrine Tumor with Thyroid Gland Metastasis: Case Report]. Journal of Surgery [Jurnalul de chirurgie] 2015;10:307-310.
77. Hood S, et al. A Patient with a Pancreatic Endocrine Tumor develops Chronic Schizophrenia: Report of a Case. J Clin Case Rep. 2013;4:328.
78. Soltermann A, et al. Lung neuro-endocrine tumors: Correlation of ubiquitinylation and sumoylation with nucleocytosolic partitioning of PTEN. Transl Med. 2015.
79. Sasaki K. Duodenal Gastrinoma Associated with Multiple Endocrine Neoplasia Type 1 (MEN1) Detected by Esophagogastroduodenoscopy (EGD), which was buried under Ulcer. J Gastrointest Dig Syst. 2016;6:418.
80. https://www.omicsonline.org/references/endoscopic-diagnosis-and-removal-of-a-duodenal-wall-gastrinoma-1227265.html
81. http://research.omicsgroup.org/index.php/Glucagonoma
82. https://www.omicsonline.org/pancreatic-disorders-and-therapy/insulinoma-top-journals-journals.php
83. Karim N, et al. Prolonged Survival in a Patient with Metastatic Vasoactive Intestinal Peptide Producing Pancreatic Neuroendocrine Tumors. J Clin Case Rep. 2012;2:210.
84. http://research.omicsgroup.org/index.php/Somatostatinoma
85. https://www.omicsonline.org/references/regression-of-a-large-malignant-gastrinoma-on-treatment-withsandostatin-lar-a-case-report-649700.html
86. http://research.omicsgroup.org/index.php/Neuroendocrine_tumor
87. http://research.omicsgroup.org/index.php/Pancreatic_neuroendocrine_tumor
88. Basso D, et al. Pancreatic Cancer Fostered Immunosuppression Privileges Tumor Growth and Progression. J Clin Cell Immunol. 2014;5:278.
89. Patel GK, et al. Pancreatic Cancer Exosomes: Shedding Off for a Meaningful Journey. Pancreat Disord Ther.
90. 2016;6:e148.
91. Yamabe A, et al. Endosonographic Diagnosis of Chronic Pancreatitis. J Gastroint Dig Syst. 2013;S2:005.
92. Pongprasobchai S, et al. Surveillance of Pancreatic Ductal Adenocarcinoma in Chronic Pancreatitis: An Ongoing Challenge. Pancreat Disord Ther. 2015;5:149.

93. Research and Reviews Journal of Medical and Health Sciences 6 e-ISSN: 2319-9865 p-ISSN:2322-0104 RRJMHS | Volume 6 | Issue 1 | February, 2017
94. Turner R. Acute Pancreatitis is a Chronic Disease. Pancreatic Dis Ther. 2013;3:118.
95. Machado NO. Groove Pancreatitis: What is its Relevance to Surgeons? Pancreatic Dis Ther. 2013;3:110.
96. http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-risk-factors
97. Yang F, et al. Diabetes Mellitus: A Risk or Protective Factor for Pancreatic Fistula after Pancreatic Resection? Pancreat Disorders Ther. 2012;2:e115.
98. Nauli AM. Pancreatic Disorders in Cancer, Diabetes, and Obesity. Pancreat Disorders Ther. 2012;2:e126.
99. Toki MI. Risk determination for pancreatic cancer. JOP. 2014;15:289-91.
100. Sellam F, et al. Epidemiology and risk factors for exocrine pancreatic cancer in a Northern African population. OMICS J Radiol. 2015;4:81.